MGI Empowers Life Sciences Industry with Revolutionary What If Campaign at XXIIIrd International Congress of Genetics

Under "What If?", MGI sets out to redirect the industry dialogue from competition and comparison of platform specifications to customer-centered solutions by prompting scientists, researchers and decision-makers to tap into the possibilities of their most pressing genomics needs and desires being met. Under "What If?", MGI sets out to redirect the industry dialogue from competition and comparison of platform specifications to customer-centered solutions by prompting scientists, researchers and...

Under "What If?", MGI sets out to redirect the industry dialogue from competition and comparison of platform specifications to customer-centered solutions by prompting scientists, researchers and decision-makers to tap into the possibilities of their most pressing genomics needs and desires being met.

Backed by its product portfolio of ultra-high, high, and medium-throughput sequencers, MGI stands out in the market with its extensive offering tailored to different sequencing needs at a competitive cost. In addition to sequencers, the company provides a one-stop-shop solution, ranging from lab automation, single-cell solutions and bioinformatics platforms including lab information management system and data management center. Under the "What If?" campaign which will gradually roll out globally, MGI continues its commitment to enabling researchers to make breakthrough discoveries and improve human health through the latest technologies and tools. What if I had a choice? What if? MGI!

For more information, please visit:  http://mgi-whatif.com/

About MGI

MGI Tech Co., Ltd. (or its affiliates, "MGI"), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments*, reagents*, and related products to support life science research, agriculture, precision medicine and healthcare. As of December 31, 2022, MGI has more than 2,800 employees, and 36% of whom are R&D personnel. Founded in 2016, MGI operates in more than 90 countries and regions, serving more than 2,000 customers.  For more information, please visit the MGI website or connect on Twitter, LinkedIn or YouTube.

*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Sweden, Italy, Czech Republic, Switzerland and Hong Kong (CoolMPS is available in Hong Kong).

*Products are provided for Research Use Only. Not for use in diagnostic procedures (except as specifically noted)

View original content:https://www.prnewswire.co.uk/news-releases/mgi-empowers-life-sciences-industry-with-revolutionary-what-if-campaign-at-xxiiird-international-congress-of-genetics-301878090.html